Watertown, MA, United States of America

Xingbin Ai


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Inventor Xingbin Ai

Introduction

Xingbin Ai is an accomplished inventor based in Watertown, Massachusetts, known for his innovative contributions in the field of biochemical research. With a focus on advancing our understanding of fibroblast growth factor (FGF) signaling, he holds a significant patent that has the potential to influence various therapeutic approaches.

Latest Patents

Xingbin Ai has been granted a patent for the "Inhibition of FGF signaling." This patent describes methods and compositions aimed at inhibiting FGF signaling through the interaction of exogenous heparan sulfate 6-O endosulfatase (Sulf1) with FGF-responsive cells. The proprietary methods include effective modifications of endogenous heparan sulfate that lead to a reduction in FGF signaling. Furthermore, the patent details how Sulf1-modified compounds can diminish the binding of FGF2 or FGF4 to FGFR1. The compositions provided in Ai's patent offer promising avenues for therapeutic applications.

Career Highlights

Ai's career is marked by his association with the Boston Biomedical Research Institute, where he has conducted pivotal research that bridges the gap between basic science and clinical applications. As an inventor, his work demonstrates a strong commitment to understanding and manipulating molecular pathways that are crucial for cellular function and disease treatment.

Collaborations

In his journey of innovation, Xingbin Ai has collaborated with esteemed colleagues, most notably Charles P Emerson, Jr. Together, they have contributed to advancements in research that address significant biomedical challenges, reinforcing the importance of teamwork in the scientific community.

Conclusion

Xingbin Ai's inventive spirit and dedication to research have paved the way for exciting developments in the understanding of FGF signaling. As he continues his work at the Boston Biomedical Research Institute, the implications of his patent and research are poised to enhance therapeutic strategies and foster further innovations in biomedical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…